OXiGENE to Commence a Randomized Clinical Trial in the United States to Evaluate CA4P for the Treatment of Patients with Non Small Cell Lung Cancer (NSCLC) WALTHAM, Mass., Feb 03, 2006 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN) -- Combretastatin A4P (CA4P) will be Evaluated with

OXiGENE to Focus Ophthalmology Strategy Toward Non-Invasive Administration of CA4P for Age-Related Macular Degeneration (AMD); Closes Enrollment of Phase II CA4P Clinical Trial in Myopic Macular Degeneration (MMD-213) WALTHAM, Mass., Sep 12, 2006 (BUSINESS WIRE) -- OXiGENE, Inc.

CORRECTION: OXiGENE Participates in 4th Annual International Conference on Antiangiogenesis WALTHAM, Mass.--(BUSINESS WIRE)--Oct. 11, 2006--This replaces the announcement made at 14:00 ET on October 10, 2006 due to the following correction: first graph, second sentence of release should read: Dr.

David Chaplin, Ph.D, Chief Scientific Officer and Head of Research and Development at OXiGENE, Named Executive Vice Chairman of the Company's Board of Directors WALTHAM, Mass., Dec 01, 2005 (BUSINESS WIRE) -- OXiGENE, Inc. (NASDAQ: OXGN, XSSE: OXGN): -- Dr.

Distinguished Oncology Researcher, Dr. Robert Kerbel, Discusses the Therapeutic Potential of Pairing Vascular Disrupting Agents with Anti-Angiogenic Drugs in the Fight against Cancer at AACR Conference WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 10, 2005--OXiGENE, Inc.

Combined Experience Includes Integral Involvement in Development of Multiple Blockbuster Oncology Products, Including Erbitux(r), Tarceva(r) and Taxol(r)

TrustPoint has the potential to improve documentation processes by automating data documentation and verification leading to improved data integrity and reduced operating expenses Collaboration represents important step for commercialization of proprietary AI/blockchain vision technology by Mateon

Treatment of stage IIB–IV melanoma due to genetic mutations that disproportionately affect pediatric patients AGOURA HILLS, Calif. , May 05, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration (FDA) granted Rare Pediatric Disease

For treatment of diffuse intrinsic pontine glioma (DIPG), a difficult to treat form of childhood brain tumor AGOURA HILLS, Calif. , Sept. 23, 2019 (GLOBE NEWSWIRE) -- Mateon Therapeutics Inc. (OTCQB:MATN) announced today that the US Food and Drug Administration ( FDA ) granted Rare Pediatric

First Patient Enrolled in OXiGENE's Phase Ib Trial of its Lead Vascular Disrupting Agent, CA4P, in Combination with an Antiangiogenic Agent, Bevacizumab (Avastin) for the Treatment of Advanced Cancer WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 8, 2006--OXiGENE, Inc.